Abivax's shares soared after reporting positive Phase III trial results for its oral ulcerative colitis drug obefazimod, triggering massive investor demand that expanded its offering to nearly $747.5 million. CEO Marc de Garidel emphasized the drug's blockbuster potential pending maintenance trial results. The funds will be allocated to advancing obefazimod’s clinical development in ulcerative colitis and Crohn’s disease, as well as commercialization planning and research. This marks a historic week for Abivax with share price multiplications across U.S. and European markets.